跳至主要内容
临床试验/NCT01140282
NCT01140282已完成不适用

Combined Exercise Program for Early Breast Cancer Survivors

University of Southern California2 个研究点 分布在 1 个国家目标入组 106 人开始时间: 2012年5月21日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
106
试验地点
2
主要终点
Changes in body composition, waist circumference, blood pressure, and serum levels of insulin, glucose, lipids, C-reactive protein, and HbA1c

研究概览

简要总结

Rationale: Exercise therapy may improve the quality of life of breast cancer survivors.

Purpose: This randomized clinical trial studies exercise therapy and quality of life in postmenopausal early breast cancer survivors receiving aromatase inhibitor therapy.

详细描述

PRIMARY OBJECTIVES:

I. To determine whether a 16-week exercise intervention will improve components of metastasis (MetS) in breast cancer survivors soon after completion of cancer-related treatments by measuring changes in body composition, waist circumference, blood pressure, and serum levels of insulin, glucose, lipids, C-reactive protein, and hemoglobin A1c (HbA1c).

II. To determine whether a 16-week exercise intervention will improve physical fitness in breast cancer survivors soon after completion of cancer-related treatments by measuring cardiorespiratory fitness and muscle strength.

III. To assesses the feasibility of a supervised exercise intervention in early breast cancer survivors.

IV. To determine whether a 16-week exercise intervention will result in a reduction in adipose tissue inflammation in obese breast cancer survivors soon after completion of cancer-related treatments by measuring ATM phenotype and ATM cytokine expression.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Newly diagnosed (I-III) with a first primary invasive breast cancer
  • Have undergone a lumpectomy or mastectomy
  • Have completed neoadjuvant/adjuvant chemotherapy and able to initiate Exercise program (if randomized to that arm) within 12 weeks of therapy completion
  • Body mass index (BMI) > 25 kg/m^2 or body fat > 30% (determined by Dr. Dieli-Conwright at baseline visit)
  • Currently participate in less than 60 minutes of physical activity per week May use adjuvant endocrine therapy if use will be continued for duration of study period
  • Nonsmokers (i.e., not smoking during previous 12 months)
  • Willing to travel to the exercise facility and USC
  • Able to provide physician clearance to participate in exercise program
  • Women of all racial and ethnic backgrounds will be included in the study enrollment process

排除标准

  • History of chronic disease including diabetes, uncontrolled hypertension or thyroid disease
  • Weight reduction >= 10% within past 6 months
  • Diagnosed with human epidermal growth factor receptor 2 (HER2)-positive tumor (exclusion due to patient use of Herceptin medication for 1 year following chemotherapy)
  • Metastatic disease
  • Planned reconstructive surgery with flap repair during trial and follow-up period
  • Cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity

研究组 & 干预措施

Arm II (Exercise)

Experimental

Patients participate in supervised exercise sessions over 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30-45 minutes once weekly for 16 weeks.

干预措施: quality-of-life assessment (Procedure)

Arm II (Exercise)

Experimental

Patients participate in supervised exercise sessions over 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30-45 minutes once weekly for 16 weeks.

干预措施: management of therapy complications (Procedure)

Arm I (Control)

Active Comparator

Patients refrain from increasing physical activity levels for 16 weeks.

干预措施: questionnaire administration (Other)

Arm I (Control)

Active Comparator

Patients refrain from increasing physical activity levels for 16 weeks.

干预措施: quality-of-life assessment (Procedure)

Arm I (Control)

Active Comparator

Patients refrain from increasing physical activity levels for 16 weeks.

干预措施: management of therapy complications (Procedure)

Arm II (Exercise)

Experimental

Patients participate in supervised exercise sessions over 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30-45 minutes once weekly for 16 weeks.

干预措施: questionnaire administration (Other)

Arm II (Exercise)

Experimental

Patients participate in supervised exercise sessions over 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30-45 minutes once weekly for 16 weeks.

干预措施: exercise intervention (Behavioral)

结局指标

主要结局

Changes in body composition, waist circumference, blood pressure, and serum levels of insulin, glucose, lipids, C-reactive protein, and HbA1c

时间窗: At week 16

Improvement of physical fitness, cardiorespiratory fitness, and muscle strength

时间窗: At week 16

Feasibility of a supervised exercise program for cancer survivors

时间窗: At week 16

Maintain positive benefits of an exercise intervention

时间窗: 12 weeks post-intervention

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验